Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

NCT00098280 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

75

Enrollment

NIH

Sponsor class

Conditions

Hemoglobinuria, Paroxysmal

Interventions

DRUG: Eculizumab

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)